The claimed technical solution relates to the field of
pharmaceutics and to dosage forms for expanding the existing range of medicaments based on a gramicidin S-containing pharmaceutical substance for use in inhibiting bacterial infections in a local
inflammation site in the human
oral cavity and in increasing the effectiveness of treatment of inflammatory infectious diseases of the
oral cavity, specifically alveolitis,
pharyngitis,
periodontal disease,
gingivitis and
stomatitis, and further relates to methods for organizing said dosage forms. The present
dosage form for inhibiting bacterial infections, which is based on a pharmaceutical substance containing gramicidin S,
chitosan and hydroxypropyl-β-
cyclodextrin, additionally contains a film-forming agent in the form of collagen, and a
plasticizer, wherein the
dosage form is produced in the form of a biodegradable buccal film having a thickness of 33-37 μm, an aqueous-extract pH of 6.8-7.2 and a T50 index for gramicidin S in relation to
human erythrocytes of 24-26 mkg / ml and is capable of
prolonged release of gramicidin S. The components of the biodegradable buccal film are present in the following proportions: 2-4 wt% gramicidin S; 30-24 wt%
chitosan; 10-15 wt% collagen; 28-32 wt% hydroxypropyl-β-
cyclodextrin; 30-25 wt%
plasticizer. The claims include 2 independent claims and 8 dependent claims.